Претраживање
Приказ резултата 51-60 од 60
Transgenic mouse, carrier of human CYP2C19 gene, as an animal model for hyperdopaminergism-induced hyperkinesia
(Elsevier Science BV, Amsterdam, 2019)
Quantification of antidepressant and antipsychotic exposure increase caused by CYP2C19 and CYP2D6 intermediate and poor metabolizer status by meta-analysis
(Elsevier, 2019)
Introduction: Most of the antipsychotics and antidepressants are metabolized by CYP2C19 and CYP2D6 enzymes. Both CYP2D6 and CYP2C19 genes are polymorphic and metabolic capacity of the enzymes is genotype-determined. ...
A novel positive modulator of alpha 4-GABAA receptors, XHe-III-74, reduces ethanol intake in mouse "drinking in the dark" model
(Elsevier Science BV, Amsterdam, 2019)
Oxytocin promotes neurotrophic growth, increases integrin subunit beta 3 (ITGB3) and ameliorates depressive- and anxiety-like behaviour in rats
(Elsevier Science BV, Amsterdam, 2017)
Alpha-lipoic acid augmentation improves negative and general psychopathology symptoms in schizophrenia
(Elsevier Science BV, Amsterdam, 2016)
Chronic magnesium administration ameliorates depressive- and anxiety-like behaviour in ACTH-treated rats
(Elsevier Science BV, Amsterdam, 2015)
Involvement of alpha(2)-adrenoceptors in the local peripheral anti-hyperalgesic effect of carbamazepine
(Elsevier Science BV, 2006)
Current level of evidence for improvement of antidepressant efficacy and tolerability by pharmacogenomic-guided treatment: A Systematic review and meta-analysis of randomized controlled clinical trials
(Elsevier B.V., 2024)
The aim of the study was to assess the clinical utility of currently available pharmacogenomic (PGx) tools compared with treatment as usual (TAU), using a meta-analysis of dichotomous and continuous antidepressant efficacy ...